Ardsley Advisory Partners’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Ardsley Advisory Partners’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-100,150	Closed	-$9.72M	–	183
2021 Q2	$9.72M	Sell	100,150 -35,400	-26%	-$2.87M	1.14%	25
2021 Q1	$9.27M	Sell	135,550 -41,450	-23%	-$3.35M	1.13%	27
2020 Q4	$15.2M	Sell	177,000 -80,000	-31%	-$6.78M	2.49%	11
2020 Q3	$16.7M	Sell	257,000 -44,900	-15%	-$2.94M	3.22%	7
2020 Q2	$22.1M	Sell	301,900 -69,350	-19%	-$3.69M	4.7%	5
2020 Q1	$12.6M	Sell	371,250 -143,250	-28%	-$6.55M	4.94%	5
2019 Q4	$28M	Sell	514,500 -149,950	-23%	-$7.43M	4.47%	5
2019 Q3	$27.7M	Buy	664,450 +403,950	+155%	+$17.1M	6.21%	2
2019 Q2	$11.4M	Buy	260,500 +250,500	+2,505%	+$14.1M	1.8%	19
2019 Q1	$515K	Buy	+10,000	New	+$432K	0.1%	79
2018 Q3	–	Sell	-10,000	Closed	-$395K	–	204
2018 Q2	$395K	Buy	+10,000	New	+$317K	0.06%	122

Other funds holding BHVN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ardsley Advisory Partners's BHVN Position: Q3 2021 in Review

Ardsley Advisory Partners sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2021, closing a stake of 100,150 shares — an estimated $9.72M sold.

Ardsley Advisory Partners first reported a position in BHVN in Q2 2018 and held it in 11 quarters. The position peaked at $28M in Q4 2019. 249 funds tracked by Wall St. Rank hold BHVN as of Q3 2021.

Ardsley Advisory Partners reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2021 after selling out during the quarter.
Ardsley Advisory Partners sold 100,150 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2021, an estimated $9.72M.
Ardsley Advisory Partners first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2018 and held it in 11 quarters.
Ardsley Advisory Partners's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $28M in Q4 2019.
249 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2021.

Based on Ardsley Advisory Partners's 13F filing for Q3 2021, filed 15 Nov 2021.